http://www.oncologynurseadvisor.com Latest articles from ONA ONA Home ONA offers clinical updates and evidence-based guidance to the oncology nurse community. Every issue includes regular coverage of topics such as safe handling and administration of chemotherapy drugs, side-effect management, new developments in specific cancers, palliative care, communication with patients and family, cancer survivorship and free continuing education credits. Home Admin@haymarketmedia.com no Can-Fite BioPharma announced that the FDA has granted its request for orphan drug designation for CF102 for the treatment of hepatocellular carcinoma. http://www.oncologynurseadvisor.com/orphan-drug-designation-for-cf102-for-hepatocellular-carcinoma/article/229126/ Thu, 23 Feb 2012 20:23:51 GMT Can-Fite BioPharma announced that the FDA has granted its request for orphan drug designation for CF102 for the treatment of hepatocellular carcinoma. ONA Significant improvements in disease-related quality-of-life (QoL) measures are seen over time following the sequential placement of bilateral cochlear implants (BiCIs) in children with prelingual deafness. http://www.oncologynurseadvisor.com/sequential-bilateral-cochlear-implantation-ups-life-quality/article/229093/ Thu, 23 Feb 2012 20:00:00 GMT Significant improvements in disease-related quality-of-life (QoL) measures are seen over time following the sequential placement of bilateral cochlear implants (BiCIs) in children with prelingual deafness. ONA Family history of thyroid cancer in a first-degree relative may be associated with an increased risk of sporadic differentiated thyroid carcinoma (DTC). http://www.oncologynurseadvisor.com/family-history-ups-risk-of-differentiated-thyroid-cancer/article/229081/ Thu, 23 Feb 2012 19:00:00 GMT Family history of thyroid cancer in a first-degree relative may be associated with an increased risk of sporadic differentiated thyroid carcinoma (DTC). ONA Nearly 25% of women undergo reexcision after partial mastectomy, with substantial surgeon and facility variation seen in rates of reexcision. http://www.oncologynurseadvisor.com/reexcision-rates-after-partial-mastectomy-vary-greatly/article/228082/ Thu, 23 Feb 2012 12:00:00 GMT Nearly 25% of women undergo reexcision after partial mastectomy, with substantial surgeon and facility variation seen in rates of reexcision. ONA Hair loss during cancer treatment is distressing and may even change the patient's sense of identity. This fact sheet addresses some common questions about hair loss. http://www.oncologynurseadvisor.com/tips-for-managing-hair-loss/article/228500/ Tue, 21 Feb 2012 14:11:17 GMT Hair loss during cancer treatment is distressing and may even change the patient's sense of identity. This fact sheet addresses some common questions about hair loss. ONA The American Cancer Society has updated its 2006 guidelines on nutrition and physical activity for cancer prevention. http://www.oncologynurseadvisor.com/acs-updates-recommendations-for-cancer-prevention/article/227193/ Tue, 21 Feb 2012 12:00:00 GMT The American Cancer Society has updated its 2006 guidelines on nutrition and physical activity for cancer prevention. ONA Cabazitaxel is a taxane derivative indicated for treatment of hormone-refractory metastatic prostate cancer in patients previously treated with a docetaxel-containing regimen. http://www.oncologynurseadvisor.com/cabazitaxel-jevtana/article/228188/ Mon, 20 Feb 2012 12:00:00 GMT Cabazitaxel is a taxane derivative indicated for treatment of hormone-refractory metastatic prostate cancer in patients previously treated with a docetaxel-containing regimen. ONA A new molecular test is more accurate at predicting high risk for death after surgical resection of early-stage nonsquamous NSCLC. http://www.oncologynurseadvisor.com/assay-can-predict-survival/article/227187/ Fri, 17 Feb 2012 12:00:00 GMT A new molecular test is more accurate at predicting high risk for death after surgical resection of early-stage nonsquamous NSCLC. ONA Nurses working in hospitals with basic electronic health records report fewer problems with patient safety and quality-related outcomes. http://www.oncologynurseadvisor.com/nurses-report-quality-of-care-is-better-with-ehrs/article/227188/ Thu, 16 Feb 2012 12:00:00 GMT Nurses working in hospitals with basic electronic health records report fewer problems with patient safety and quality-related outcomes. ONA Although the risks of erythropoietin-stimulating agents can outweigh the benefits, select patients may benefit from these drugs. http://www.oncologynurseadvisor.com/using-esas-in-patients-with-cancer-related-anemia/article/223165/ Wed, 15 Feb 2012 21:55:00 GMT Although the risks of erythropoietin-stimulating agents can outweigh the benefits, select patients may benefit from these drugs. ONA An antibody-drug conjugate indicated for the treatment of Hodgkin lymphoma and sALCL after failure of prior multiagent regimens. http://www.oncologynurseadvisor.com/brentuximab-vedotin-adcetris/article/215527/ Mon, 19 Dec 2011 19:00:00 GMT An antibody-drug conjugate indicated for the treatment of Hodgkin lymphoma and sALCL after failure of prior multiagent regimens. ONA VADs enable long-term IV therapy; however, the devices and their use pose a unique set of challenges for nurses. http://www.oncologynurseadvisor.com/troubleshooting-complications-of-vascular-access-devices/article/216871/ Thu, 15 Dec 2011 23:33:00 GMT VADs enable long-term IV therapy; however, the devices and their use pose a unique set of challenges for nurses. ONA